mTOR/STAT3-IN-1

mTOR/STAT3-IN-1 (Compound 4j) (1-50 μM; 72 h) exerts cell type-dependent antiproliferative activity against BJ, RPE-1 hTERT and U-251 MG cells when applied at concentrations of 10 μM and 50 μM for 72 h^[1].
mTOR/STAT3-IN-1 (1-50 μM; 72 h) inhibits the proliferation of BJ cells and induces vacuolization in BJ cells at concentrations of 10 μM and 50 μM after 72 h of treatment, but exhibits no cytotoxicity at concentrations up to 50 μM^[1].
mTOR/STAT3-IN-1 (10-50 μM; 72 h) reduces the number of viable cells in Docetaxel (HY-B0011)-induced senescent BJ cells and γ-ray-induced senescent RPE-1 cells when applied at concentrations of 10 μM and 50 μM for 72 h^[1].
mTOR/STAT3-IN-1 (50 μM; 72 h) reduces the confluence of Docetaxel-induced senescent BJ cells, but no cell death induced by it is detected via propidium iodide staining^[1].
mTOR/STAT3-IN-1 (0.1-100 μM; 1-5 h) potently inhibits mTOR pathway activity in BJ cells. It completely inhibits the phosphorylation of p70 S6 kinase at concentrations ≥ 12.5 μM, with an IC₅₀ value of 0.51 μM at 1 h and 0.87 μM at 5 h^[1].
mTOR/STAT3-IN-1 (100 μM; 30 min) slightly inhibits IL-6-induced phosphorylation of STAT3 at Tyr705 in RPE-1 hTERT cells at a concentration of 100 μM^[1].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.